|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期1973-01-22 |
A Phase IIa Multicenter Double Blind Study to Evaluate the Efficacy and Safety of Low Doses of Oral NT-KO-003 for the Treatment of Multiple Sclerosis
The aim of the study is to assess the efficacy and safety of NT-KO-003 in the treatment of relapsing remitting multiple sclerosis, comparing two doses versus placebo.
100 项与 Neurotec Pharma SL 相关的临床结果
0 项与 Neurotec Pharma SL 相关的专利(医药)
100 项与 Neurotec Pharma SL 相关的药物交易
100 项与 Neurotec Pharma SL 相关的转化医学